Clinical trials: Treatment naïve
Hepatitis C, HIV
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
This study consists of 2 parts, Part A and Part B. Part A, the Phase 1 drug interaction/early viral kinetic study, will evaluate the effect of selected antiretroviral therapies on the safety, viral kinetics, and pharmacokinetics…
- Trial name
- NCT01565889
- Testing
- SOF, EFV/FTC/TDF, EFV
- Where
- Puerto Rico
- Volunteers
- 52 people
- Sponsor
- Gilead Sciences
Type 2 Diabetes (T2D)
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
This study is an open-label, 1:1 randomized, active-controlled, 2-arm, 20-week treatment duration, parallel-group, multicenter, phase IV study to evaluate the effect of iGlarLixi versus Gla-100 on glycemic control measured as TIR…
- Trial name
- China Soli-CGM (NCT06671587)
- Testing
- iGlarLixi (insulin glargine/lixisenatide), Gla-100 (insulin glargine)
- Where
- China
- Volunteers
- 678 people
- Sponsor
- Sanofi
HIV Infections
Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection
The primary objective of the study is to evaluate the pharmacokinetic behavior of Suc-HSA after consecutive daily intravenous (i.v.) doses.
- Trial name
- NCT00128063
- Testing
- succinylated human serum albumin
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- International Antiviral Therapy Evaluation Center
Mucopolysaccharidosis (MPS), Hunter Syndrome
A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)
The main aim of this study is to evaluate the ability of a prophylactic immune tolerizing regimen (ITR) to prevent or reduce the development of high titer anti-idursulfase antibodies in treatment-naïve participants with Hunter…
- Trial name
- NCT05494593
- Testing
- ELAPRASE, Rituximab, Methotrexate
- Where
- 8 sites in United States
- Sponsor
- Takeda
Non-Small Cell Lung Cancer
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer
A single-arm, open-label, two-stage multicenter, phase II study. Patients were pre-screened for ALK positive status. Treatment with LDK378 at 750 mg qd was continued until the patient experienced unacceptable toxicity that…
- Trial name
- NCT01685138
- Testing
- LDK378
- Where
- 51 sites in United States, Australia and 16 more
- Volunteers
- 124 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
Contribution of Bone to Urine Citrate
Identification of the mechanisms by which bone contributes to urine citrate could lead to alternative explanations for and approaches to hypocitraturia.
- Trial name
- NCT06811363
- Testing
- Metabolic / prescribed diet, KCit Load (40 meq), Anti-resorptive agents
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Texas Southwestern Medical Center
HIV-1 Infection
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of doravirine/islatravir (DOR/ISL [MK-8591A]) in treatment-naïve participants with…
- Trial name
- NCT05705349
- Testing
- DOR/ISL, BIC/FTC/TAF
- Where
- 131 sites in United States, Argentina and 19 more
- Volunteers
- 537 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Acquired Immune Deficiency Syndrome
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease
The ideal anti-HIV medications for patients with advanced HIV disease is unknown. There is evidence that anti-HIV regimens that contain protease inhibitors can enhance immune function better than regimens that do not contain…
- Trial name
- NCT00775606
- Testing
- Lopinavir 400 mg/ritonavir 100 mg, Efavirenz
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Rush University Medical Center
Hypertension, Pulmonary
A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).
The Study Hypothesis: Aggressive, upfront, dual therapy for treatment-naïve NYHA I/II/III PAH is superior to a traditional "step-up" approach. The study will evaluate: 1.
- Trial name
- NCT01305252
- Testing
- treprostinil inhalations, tadalafil
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Stanford University
NSCLC
A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2.
- Trial name
- PIONEER (NCT00269828)
- Testing
- paclitaxel, paclitaxel poliglumex
- Where
- 143 sites in United States, Argentina and 9 more
- Volunteers
- 600 people
- Sponsor
- CTI BioPharma
Macular Edema, Retinal Vein Occlusion
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
- Trial name
- BEACON (NCT04592419)
- Testing
- KSI-301, Aflibercept
- Where
- 141 sites in United States, Czechia and 10 more
- Volunteers
- 568 people
- Sponsor
- Kodiak Sciences Inc
Acute Myeloid Leukemia
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult participants who are ineligible for…
- Trial name
- VALOR (NCT05215639)
- Where
- 19 sites in Austria, Switzerland
- Volunteers
- 120 people
- Sponsor
- AbbVie
Peripheral T-cell Lymphoma
A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma
The study is being conducted to evaluate the safety and efficacy of SHR2554 with CHOP/CHOEP in treatment- naïve peripheral T-cell lymphoma.
- Trial name
- NCT06173999
- Testing
- SHR2554/CHOP, SHR2554/CHOEP
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diffuse, Large B-Cell, Lymphoma
A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
The purpose of this study is to comparing the Efficacy and Safety between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients.
- Trial name
- NCT02867566
- Testing
- IBI301 plus CHOP, Rituximab plus CHOP
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
HIV
Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment
The purpose of this research study is to compare changes in triglyceride and other lipids (levels of fats found in the blood) from Baseline (Day 1) to Week 12 for darunavir/ritonavir 800/100 mg once daily versus…
- Trial name
- NCT00757783
- Testing
- ritonavir, darunavir, emtricitabine [FTC]/tenofovir [TDF]
- Where
- 15 sites in United States
- Volunteers
- 68 people
- Sponsor
- Tibotec, Inc
HIV
Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia
One hundred subjects in Russia will be treated with a combination of Combivir (zidovudine and lamivudine) and maraviroc as their first line HIV therapy.
- Trial name
- NCT01275625
- Testing
- HIV therapy
- Where
- 8 sites in Russia
- Volunteers
- 98 people
- Sponsor
- ViiV Healthcare
Cardiovascular Risk Factor, Blood Pressure
Comparison of Acute Sauna With Exercise and Sauna
Sauna bathing has been associated with a lower risk for cardiovascular disease (CVD) outcomes, improved vascular endothelial and cardiac function, reduced oxidative stress and lower blood pressure.
- Conditions
- Cardiovascular Risk Factor, Blood Pressure, Arterial Stiffness
- Trial name
- NCT04556422
- Testing
- Aerobic exercise, Sauna bathing
- Where
- Finland
- Volunteers
- 72 people
- Sponsor
- University of Jyvaskyla
Diabetes Mellitus, Type 2
Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure
Primary objective: To demonstrate the superiority of insulin glargine over liraglutide in terms of percentage of patients reaching a Glycosylated Haemoglobin (HbA1c) < 7% at the end of the comparative period (24 weeks) in Type 2…
- Trial name
- EAGLE (NCT01117350)
- Testing
- Insulin glargine, Liraglutide, Metformin
- Where
- 136 sites in United States, Austria and 15 more
- Volunteers
- 978 people
- Sponsor
- Sanofi
Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA
Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis
This study is researching a Regeneron drug called linvoseltamab ("study drug") alone compared to standard of care (SoC) combination to see if it can help treat participants who are newly diagnosed and previously untreated for…
- Trial name
- LINKER-AL1 (NCT07901725)
- Testing
- Linvoseltamab, Daratumumab, Bortezomib
- Volunteers
- 382 people
- Sponsor
- Regeneron Pharmaceuticals
Hepatitis C Virus (HCV)
ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
This is a study to evaluate ABT 450/r/ABT-267 and ABT-333 in treatment-naïve and treatment-experienced Asian adults with subgenotype 1b chronic HCV without cirrhosis.
- Trial name
- NCT02517515
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir
- Volunteers
- 650 people
- Sponsor
- AbbVie